Overview

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Status:
Active, not recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA (with and without JNJ-56136379) and of JNJ-56136379+NA.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Sciences Ireland UC